This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mocikat, R. Articles by Lindhofer, H. Search for Related Content PubMed PubMed Citation Articles by Mocikat, R. Articles by Lindhofer, H.

Trioma-based Vaccination against B-Cell Lymphoma Confers Long-Lasting Tumor Immunity

GSF-Institut für Immunologie, Marchioninistrasse 25, D-81377 München, Germany

A major goal of tumor immunotherapy is the induction of a systemic immune response against tumor antigens such as the tumor-specific immunoglobulin idiotype (Id) expressed by lymphomas of the B-cell lineage. We describe an approach based on specific redirection of the tumor Id toward professional antigen-presenting cells (APCs), thereby overcoming the inefficient presentation on the parental transformed B cell. Lymphoma cells are fused to a xenogeneic hybridoma cell line that secretes an antibody against a surface molecule on APCs. Due to preferential assembly between heavy and light chains of antibodies of different speciesorigin, the resulting "trioma" cells produce at high yield a bispecific antibody containing the lymphoma Id and the APC-binding arm, which redirects the Id to APCs. Processing and presentation of the Id will lead to T-cell activation. An absolute requirement for inducing a complete tumor protection was the immunization with antibody-secreting trioma cells as a cell-based vaccine instead of the soluble bispecific antibody. Tumor immunity was specific and long-lasting. Both CD4⁺ and CD8⁺ T cells were necessary for inducing tumor immunity.

¹ To whom requests for reprints should be addressed. Phone: (49) 89/7099-313; Fax: (49) 89/7099-300; E-mail: mocikat@gsf.de.

Received 2/ 4/97. Accepted 4/30/97.

This article has been cited by other articles:

				B. Schlereth, I. Fichtner, G. Lorenczewski, P. Kleindienst, K. Brischwein, A. da Silva, P. Kufer, R. Lutterbuese, I. Junghahn, S. Kasimir-Bauer, et al. Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct Cancer Res., April 1, 2005; 65(7): 2882 - 2889. [Abstract] [Full Text] [PDF]

				U. Wahl, E. Nossner, K. Kronenberger, R. Gangnus, H. Pohla, M. S. Staege, H.-J. Kolb, M. Hallek, and R. Mocikat Vaccination against B-cell Chronic Lymphocytic Leukemia with Trioma Cells: Preclinical Evaluation Clin. Cancer Res., September 15, 2003; 9(11): 4240 - 4246. [Abstract] [Full Text] [PDF]

				K. Heckelsmiller, K. Rall, S. Beck, A. Schlamp, J. Seiderer, B. Jahrsdorfer, A. Krug, S. Rothenfusser, S. Endres, and G. Hartmann Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model J. Immunol., October 1, 2002; 169(7): 3892 - 3899. [Abstract] [Full Text] [PDF]

				K. Kronenberger, A. Dieckmann, M. Selmayr, J. Strehl, U. Wahl, H. Lindhofer, G. Kraal, and R. Mocikat Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells Blood, February 15, 2002; 99(4): 1327 - 1331. [Abstract] [Full Text] [PDF]

				P. Ruf and H. Lindhofer Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody Blood, October 15, 2001; 98(8): 2526 - 2534. [Abstract] [Full Text] [PDF]

				O. Egeter, R. Mocikat, K. Ghoreschi, A. Dieckmann, and M. Röcken Eradication of Disseminated Lymphomas with CpG-DNA Activated T Helper Type 1 Cells from Nontransgenic Mice Cancer Res., March 1, 2000; 60(6): 1515 - 1520. [Abstract] [Full Text]

				R. Zeidler, G. Reisbach, B. Wollenberg, S. Lang, S. Chaubal, B. Schmitt, and H. Lindhofer Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing J. Immunol., August 1, 1999; 163(3): 1246 - 1252. [Abstract] [Full Text] [PDF]